相关实验视频

Updated: Jul 19, 2025

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

维护化疗治疗与狂宫肌肉瘤患者

Gianni Bisogno^1,2, Veronique Minard-Colin³, Meriel Jenney⁴

¹Department of Women's and Children's Health, University of Padua, 35128 Padua, Italy.

|August 12, 2023

概括

维护化疗 (MC) 改善了高风险狂宫肌肉瘤 (RMS) 的存活率. 2005年RMS试验显示,使用MC的结果更好,尽管需要进一步研究最佳药物组合和RMS治疗持续时间.

科学领域:

儿科瘤学儿科瘤学
医学瘤学医学瘤学
癌症研究癌症研究

背景情况:

维持化疗 (MC) 涉及长时间的低强度化疗,以维持瘤缓解.
脊髓髓瘤瘤 (RMS) 是一个重要的儿科癌症,需要有效的治疗策略.
之前的研究表明,在特定的RMS患者群体中,MC具有潜在的益处.

研究的目的:

更新RMS2005试验中关于MC在高风险局部RMS中的疗效的研究结果.
审查和讨论现有的关于MC在rhabdomyosarcoma应用的文献.
确定未来在MC治疗RMS的研究领域.

主要方法:

分析RMS2005试验的最新结果,比较接受MC治疗的患者与未接受MC治疗的患者.
系统的文献搜索关于RMS中MC的研究,包括随机试验和非随机研究.
在复发性RMS病例中评估MC可行性和耐受性.

主要成果:

在RMS2005试验中,接受MC的患者表现优异,无病存活期5年 (78.1%与70.1%) 和整体存活率 (85.0%与72.4%) 较高.
一项审查发现了七篇关于RMS中MC的论文,但只有一个随机试验未能显示特定的MC治疗方案的优势.
非随机化研究表明,与高剂量化疗相比,MC的结果更好,包括转移患者,并证明了在复发的RMS中可行性.

结论:

MC,特别是维诺雷尔宾和低剂量环胺,似乎可以改善高风险局部RMS的存活率.
关于RMS中MC的证据是混合的,结果因治疗方案和研究设计而异.
需要进一步调查以确定最佳的MC药物组合和RMS治疗持续时间,正在进行的试验旨在解决这些问题.

关键词:

低剂量化疗是一种低剂量化疗.维护化疗是维持化疗的方法.计量学化学疗法计量学化学疗法拉布多米索科马 (rhabdomyosarcoma) 是一种肌肉癌.

更多相关视频

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...